Newsfeeds - Spark Newswire

1 minute read

Aquestive Therapeutics Sees FY23 Revenue $37M-$41M Vs $37.83M Est.

Today, 7:08 PM

2023 Outlook Aquestive is providing its full year 2023 financial outlook. The Company expects: Guidance Total revenue (in millions) $37 to $41 Non-GAAP adjusted EBITDA

AQST

2 minute read

News

On Dec 30, 2022, Aquestive Therapeutics Received Notice Of Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq

By Happy Mohamed

Today, 7:08 PM

On December 30, 2022, Aquestive Therapeutics, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule

AQST

1 minute read

Alliance Global Partners Maintains Buy on Aquestive Therapeutics, Lowers Price Target to $7

By Benzinga Newsdesk

Today, 7:08 PM

Alliance Global Partners analyst James Molloy maintains Aquestive Therapeutics (NASDAQ:AQST) with a Buy and lowers the price target from $10 to $7.

AQST

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 7:08 PM

Gainers Benitec Biopharma (NASDAQ:BNTC) shares increased by 9.8% to $0.35 during Tuesday's after-market session. The company's market cap stands at $9.0 million.

ANPC

1 minute read

Aquestive’s AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction

By Vandana Singh

Today, 7:08 PM

Aquestive Therapeutics Inc (NASDAQ:AQST) announced positive topline results from the EPIPHAST 2 trial for its AQST-109 epinephrine sublingual film. The trial…

AQST

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 7, 2022

By Benzinga Insights

Today, 7:08 PM

Upgrades

ACCD

3 minute read

Why Coupa Software Is Trading Higher By Over 12%; Here Are 24 Stocks Moving Premarket

By Lisa Levin

Today, 7:08 PM

Gainers Biophytis S.A. (NASDAQ: BPTS) shares rose 41.5% to $1.33 in pre-market trading after the company announced data on Covid treatment.

ALNA

1 minute read

Oppenheimer Initiates Coverage On Aquestive Therapeutics with Outperform Rating, Announces Price Target of $8.5

By Benzinga Newsdesk

Today, 7:08 PM

Oppenheimer analyst Francois Brisebois initiates coverage on Aquestive Therapeutics (NASDAQ:AQST) with a Outperform rating and announces Price Target of $8.5.

AQST

2 minute read

Movers

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 7:08 PM

Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average volume over the last 100 days. The company's market cap stands at $22.7 million.

APGN